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Climate change has been described as the “greatest threat to global 
public health in the 21st century”.1,2 On 1 May 2019, the United 
Kingdom was the first country in the world to declare a “climate 
emergency”3 in response to the Intergovernmental Panel on Climate 
Change report in 2018. The primary method for combating climate 
change is to reduce greenhouse gas emissions (GHGEs)4 and the UK 
government has committed to achieving net zero GHGEs compared 
to a 1990 baseline by 2050.5,6 In order to achieve this goal, a number 
of sectors will need to reduce their emissions. One of these sectors 
is the UK National Health Service (NHS), which is the UK’s largest 
public sector greenhouse gas emitter.6-8 Importantly, around 3.5% 
of the NHS’s carbon footprint is derived from a single treatment - 
pressurized metered dose inhalers (pMDIs) 8-11 which are used in the 
management of asthma and chronic obstructive pulmonary disease 
(COPD). The inhaler constituent responsible for 96% of pMDI’s glob-
al-warming potential (GWP), is not the active ingredient but rather 
the propellant.3,12 Dry powder inhalers (DPIs) which rely on a pro-
pellant-free mechanism that significantly reduces the environmental 
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Climate change has been described as the biggest global health threat of the 21st 
century.	 As	 a	 result,	 governments	 around	 the	world	 are	 committing	 to	 legislative	
change in order to reduce greenhouse gas emissions (GHGEs). The healthcare sector 
makes a significant contribution to GHGEs and in line with national legislation in the 
UK, the NHS has recently committed to achieving net zero emissions by 2050. The 
management of asthma and COPD largely depends on the prescribing of medica-
tions that are delivered through inhalers. In the UK, the use of pressurized metered 
dose	inhalers	(pMDIs),	which	rely	on	hydrofluorocarbon	(HFC)	propellants	accounts	
for 3.5% of the NHS’s total carbon footprint. In contrast, dry powder inhalers (DPIs) 
have	a	much	lower	carbon	footprint	due	to	the	absence	of	a	HFC	propellant.	Here	
we review evidence of the impact of inhaler choices across four domains: environ-
mental impact, clinical effectiveness, cost effectiveness and patient preferences. We 
find that as well as a lower global-warming potential, DPIs have additional benefits 
over pMDIs in other domains and should be considered first line where clinically 
appropriate.
K E Y W O R D S
climate change, inhalers, sustainable prescribing
2 of 6  |     STARUP-HANSEN ET Al.
impact of the prescription are the favored choice in a number of 
European countries13—although this is also due to nonenvironmental 
factors	such	as	local	manufacturing.	A	priority	of	the	UK’s	Sustainable	
Development Unit (SDU) strategy is to achieve an 80% reduction in 
NHS’s GHGE by 2050 and this involves switching from propellant to 
DPI	inhalers	which	have	a	lower	GWP	(Figure	1).6,14
Climate change and its related health risks15 is a driver for the 
reduction in the number of pMDIs prescribed in the UK. Here we 
review the evidence for the environmental impact of pMDIs, which 
is now well established.6,16-18 We also consider the clinical and cost 
effectiveness and patient preference of DPI vs pMDI inhalers and 
propose that these factors are not necessarily barriers to switching 
to inhaler devices with lower GWP.
2  | ENVIRONMENTAL IMPAC T
pMDIs have a significantly higher GWP, due to their hydrofluoroal-
kane	(HFA)	propellants,	which	are	quoted	to	be,	gram	for	gram,	up	
to 3800 times a more powerful greenhouse gas than carbon diox-
ide.10,19	The	DPI,	which	does	not	require	a	propellant,	has	a	carbon	
footprint 18 times lower than MDIs.18-20 Wilkinson et al17 calculated 
that if 10% of UK pMDI inhalers were replaced with their corre-
sponding DPI devices, more than 68.6 kilo tonnes of CO2	 equiva-
lent	could	be	saved	each	year.	This	is	equivalent	to	the	mass	of	CO2 
produced from 43 thousand roundtrip transatlantic flights (return 
economy	flights	from	London	to	New	York).21
A	study	comparing	carbon	footprints	of	the	entire	 life-cycle	of	
various inhalers including their productive and distribution found 
that MDI devices had up to 30 times larger carbon footprints than 
DPI	equivalents	and	that	 these	differences	were	mainly	 related	to	
the use phase and end-of-life (disposal) phase.22 It was calculated 
that if England applied the Swedish distribution of pMDIs and DPIs, 
550 kt of CO2 would be saved annually—which corresponds to ap-
proximately 2.6% of NHS England’s total carbon footprint.22
Furthermore,	 the	 inappropriate	 disposal	 of	 pMDIs	 contributes	
further to their environmental impact.23	Although	some	pMDIs	do	
have dose counter mechanisms, this is not universal (in contrast 
to DPIs) and means that patients may not know how many doses 
are left in their inhalers. This creates two problems: firstly, patients 
can unknowingly run out of doses which is potentially catastrophic 
during an acute exacerbation of asthma or COPD; and secondly, it 
leads	to	patients	being	more	 likely	 to	request	 repeat	prescriptions	
earlier than necessary.24 The inappropriate disposal of pMDI devices 
with unused doses is especially concerning as not only does it in-
crease the prescribing burden but devices no longer in use continue 
to release greenhouse gases into the atmosphere.23 In a UK study, 
inhalers that had been disposed of incorrectly were collected over 
90 days from one local district hospital and this resulted in enough 
pMDIs	 to	produce	an	equivalent	of	2.63	 tonnes	of	CO2 emissions 
which would otherwise have been released into the atmosphere.23 
The	 recent	 British	 Thoracic	 society	 position	 statement	 on	 “The	
Environment	 and	 Lung	Health”25 highlights the importance of ad-
vising patients on avoiding disposal of inhalers in landfill sites and of 
supporting recycling schemes through pharmacies.
It should be noted that DPIs have limited benefit in some en-
vironmental domains not related to climate change. This is seen in 
Jeswani et al’s study26 which found that although DPIs can reduce 
the climate change impact of inhalers by 96% if they replace pMDIs, 
this comes at a cost in domains such as marine eutrophication and 
fossil depletion, which should be acknowledged.
In view of the legal obligations to reduce GHG emissions to-
gether with the health benefits of climate change mitigation, a move 
away from pMDIs to DPIs seems increasingly important.
3  | CLINIC AL EFFEC TIVENESS
Concerns about the effectiveness of each inhaler needs to be ad-
dressed. In 2005, Dolovich et al’s20 systematic review found no 
F I G U R E  1   This graph shows the 
potential impact of a shift from propellant 
inhalers on carbon emissions in the 
context of other global, national and 
health sector actions14
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significant differences in the efficacy of different inhaler types, in-
cluding pMDIs and DPIs in both asthma and COPD patients in all 
clinical situations examined. However, the reviewed RCTs only in-
cluded	patients	with	a	perfect	inhaler	technique.	This	is	important,	
as the conclusion may not represent the “real world efficacy”, in 
which patients do not always use their inhalers correctly.
pMDIs deliver the drugs into the airways through a propellant 
mechanism.	Failure	 in	 coordinating	actuation	of	 the	 inhaler	with	a	
long slow inspiration by the patient is the most significant problem 
for patients using pMDIs.27 When using DPIs, the drug is pulled 
into the lungs as a result of the patients’ own inspiratory effort and 
therefore, when using a DPI, poor coordination becomes less of a 
barrier to effective therapy.28 In fact, it has been widely reported 
that	 the	 proportion	 of	 patients	 using	 the	 correct	 technique	 with	




internal resistance of the inhaler. Using a Turbohaler©,	PIFs	>30	L/
min have been shown to be sufficient for effective administration 
in both adult and children populations.29,30	 As	 disorders	 primarily	
affecting expiration, both COPD and asthma do not significantly 
limit	individual	PIF	rates.	However,	clinicians	should	be	aware	that,	
DPIs are not the appropriate choice of inhaler for patients who are 
not	able	 to	generate	sufficient	 inspiratory	 flow.	For	example,	 frail,	
elderly patients, selected patients with COPD, very young patients 
or those with muscle weakness. Pederson et al29 showed that 25% 
of children 3-5 years of age were not able to, and Janssens et al31 
showed that up to 30% of elderly COPD patients were not able to 
achieve	rates	of	45	L/min	via	various	DPI	devices.
Nonetheless, when considering effectiveness of drug delivery, 
DPIs should be considered in clinical scenarios where both inhaler 
types are appropriate while recognizing that some patients will need 
to be provided with a pMDI in a rescue pack for use in the case of 
an acute exacerbation. The UK National Institute for Health and 
Care Excellence (NICE) has produced a patient decision aid for pa-
tients with asthma that suggests a DPI device is suitable and should 
be considered for asthma patients who can breathe in deeply for 
2-3 seconds independent of their coordination or ability to take a 
longer 4-5 second breath.32
4  | COST EFFEC TIVENESS
The apparent higher financial cost associated with DPIs compared 
to pMDIs has long been a barrier to their widespread use in the 
NHS.17,27	This	 is	because	 the	pMDI	version	of	 the	 frequently	pre-
scribed short-acting bronchodilators for asthma and COPD are less 
expensive than their DPI counterparts.17,33 However, other medica-
tions,	especially	combination	inhalers	of	Long-Acting-Beta-Agonists	
and Inhaled Corticosteroids are cheaper in DPI formulations com-
pared to pMDIs.17 Interestingly, a cost analysis of community inhaler 
prescriptions concluded that although a widespread switch from 
pMDI to DPIs would result in an increase in short-acting bronchodi-
lator associated costs, this would be offset by the savings made with 
other inhaled medications. Overall, it was modeled that for every 
10% of pMDIs that are replaced by cheapest DPI alternatives, more 
than £8.24 million could be saved annually.17 Similarly, Korean and 
South Indian studies have failed to show a significant difference in 
overall costs between DPI and pMDI.34-36 This renders the historical 
assumption	of	DPIs	being	more	expensive	than	pMDIs	as	question-
able and hence should not be seen as a barrier to DPI prescriptions. 
In fact, the modeled economic benefits of switching to DPIs pro-
vides a further driver to change inhaler devices prescribing practice.
5  | PATIENT PREFERENCE
Unsurprisingly, ease of use has been identified as one of the most im-
portant considerations for patients and healthcare professionals in 
the choice of inhalers.37 The 2017 study by Ramadan et al38 explored 
the satisfaction of 246 asthma and COPD patients treated with ei-
ther DPI and/or pMDI and discovered that a significantly greater 
percentage (73% vs 46%) of DPI users found their inhaler easy to use 
and were more satisfied with their care compared to pMDI users. 
Furthermore,	a	2011	study39 investigated the response when COPD 
patients previously treated with pMDI were switched to a DPI and 
given inhaler training during a hospital visit for an acute exacerba-
tion	 of	 their	 condition.	 Findings	 indicate	 that	 3	 months	 after	 the	
switching intervention, the majority of switched patients remained 
on the DPI. This not only illustrated that some patients may have 
preferred using a DPI but also that it is feasible to make simple inter-
ventions to switch patients currently treated with a pMDI to a DPI 
successfully. It is important to note that nonconsensual switching 
of inhalers, without appropriate instruction regarding inhaler tech-
niques	can	 lead	 to	worse	clinical	outcomes	 for	COPD	and	asthma	
patients.40 However, Price et al41 have shown that outcomes after 
consensual switching of inhalers with face-to-face online consulta-
tions did not lead to any reduction in clinical effectiveness. In ad-
dition, a more recent study42 attempted to address the paucity of 
information about patients and physician attitudes to the choice of 
inhalers and surveyed 50 NHS patients who were already using their 
inhalers. This found that 44% of those patients expressed that the 
carbon footprint of their inhaler is “important” or “very important” 
to them. We concede that this is a small sample size and that more 
research	into	this	area	is	required.	Importantly,	in	line	with	other	re-
search, it also found that 80% of those surveyed rated ease of use of 
inhalers as “important” or “very important”. Overall, using a patient-
centered approach to inhaler prescribing that takes into account pa-
tients’ preferences is important. Some patients will choose to use 
or remain on a pMDI but there is evidence that for some patients 
a DPI will be preferable. Device options should be discussed with 
patients and clinicians should feel confident to start a DPI or switch 
a pMDI inhaler to a DPI when clinically appropriate if patients are in 
agreement.	Appropriate	advice	as	well	as	regular	technique	reviews	
should also be offered.
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6  | CURRENT GUIDELINES
Currently, guidelines in the UK regarding the choice of inhalers do 
not make an appropriate emphasis on the potential carbon savings 
that could be achieved when selecting DPIs over pMDIs. In fact, the 
July 2019 NICE guidance for COPD diagnosis43 and management 
does not offer any advice regarding deciding between pMDIs and 
DPIs and contains no information on the environmental impact of 
each	 device.	 However,	 in	 asthma	management,	 the	 recent	 British	
Thoracic	Society	(BTS)	guidance	does	now	advise	that	“Prescribers, 
pharmacists and patients should be aware that there are significant 
differences in the global-warming potential of different MDIs and that 
inhalers with low global-warming potential should be used when they 
are likely to be equally effective”.34 This is an encouraging develop-
ment but is short of explicitly recommending the DPIs (which have 
a ‘lower global-warming potential’) as the preferred choice based on 
similar efficacy, higher patient preference and lower climate impact. 
The patient decision aid on inhaler devices for asthma published by 
NICE also includes a discussion of the environmental impact of dif-
ferent inhalers.32
Although	there	 is	a	 lack	of	research	into	clinician	awareness	of	
the carbon footprint of different inhaler types, there is certainly 
scope to increase this awareness and potentially alter prescribing 
decisions	through	a	greater	emphasis	 in	clinical	guidelines.	For	the	
busy clinician, guidelines should highlight boldly that DPIs are the 
preferred inhaler type under circumstances when both pMDIs and 
DPIs are appropriate for the patient.
7  | CONCLUSIONS AND 
RECOMMENDATIONS
Climate change is an existential threat to the entire population of this 
planet and because of this, all societal sectors must adopt changes 
to	reduce	GHG	emissions.	A	shift	in	inhaler	devices	prescribing	prac-
tices in favor of DPIs and away from pMDIs, where clinically appro-
priate, has the potential to significantly reduce healthcare associated 
GHGEs.6 Moreover, as well as the well-documented environmental 
benefits, a switch towards DPI devices should be supported as DPIs 
are at least as effective, potentially cheaper and are often are pre-
ferred by patients.
In	accordance	with	 the	NHS	Long	Term	Plan	 to	 “shift	 to	 lower	
carbon inhalers”44 our recommendations are that national and local 
guidelines are updated; guidance should consider the potential ben-
efits of advising DPIs as the device of choice in new diagnoses of 
asthma and COPD as well as the benefits of switching patients cur-
rently using pMDIs to DPIs where clinically appropriate. We recog-
nize the short-term financial impact on the local health economy but 
also highlight potential long-term cost savings.
Some concerns have been expressed in response to the propos-
als to reduce pMDI prescribing in the UK.45 In line with others,8 we 
are not advocating for a total switch from pMDIs to DPIs and recog-
nize that some patients will have valid reasons to continue to use a 
pMDI but instead aim to explore the relative advantages and disad-
vantages of changing prescribing practice. It is the role of the health-
care professional to ensure that their patient’s condition is managed 
optimally with appropriate attention paid to their preferences and 
that patients are able to manage their symptoms effectively in part-
nership with their clinical team.
We	recognize	that	HFCs	are	widely	used	globally	across	many	
different sectors such as air conditioning and refrigeration and 
their use in inhalers represents only a small proportion of this vol-
ume; the counter-argument to this is that action is being taken to 
reduce this across these sectors46 and healthcare should not be ex-
empt	from	being	required	to	take	action.	Equally,	while	pMDIs	con-
tribute only a small proportion of the carbon footprint of the NHS, 
if this can be reduced with no negative impacts on patients then 
we would argue that this should be prioritized along with other 
measures taken to make healthcare more sustainable. It is there-
fore appropriate that this is also addressed within the healthcare 
sector and that healthcare workers, as professionals advocating 
for the health of the public that they serve, would want to ensure 
that the contribution of healthcare to climate change is minimized 
as far as possible.
Future	research	should	focus	on	evaluating	clinician	awareness	
of the environmental benefits of DPI inhalers and evaluating the im-
pact	of	a	change	in	guidelines	on	the	prescribing	of	inhalers.	Finally,	
timely implementation of a large number of environmental measures 
is essential to reverse the environmental catastrophe that is cur-
rently unfolding.
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